Liver diseases such as cirrhosis and liver cancer are killing hundreds of people each day across the WHO European region, according to a commentary published in The Lancet. The second European Association for the Study of the Liver (EASL)–Lancet Commission on liver health in Europe arrives at a critical juncture for public health.
This burden is often misunderstood as a niche clinical concern, the authors argue, when in fact it forms a significant and neglected component of the region's non-communicable disease (NCD) crisis. The commission builds upon recommendations from the first EASL–Lancet report published in 2021.
The commentary, which cites the commission's work, underscores that liver diseases exact a heavy toll on individuals, health systems, and entire economies. Hundreds of daily deaths from these preventable conditions represent a persistent failure to translate existing evidence into effective policy.
The authors argue that translating research into actionable liver health policy is essential to reversing these trends. Without concerted government action, the human and economic costs will continue to mount across Europe.
The EASL–Lancet Commission's forthcoming recommendations are expected to outline specific targets for screening, treatment access, and public awareness campaigns.